Recent Advances on Chitosan-Based Nanoparticles for Brain Drug Delivery

Последние достижения в области наночастиц на основе хитозана для доставки лекарственных средств в мозг
Amani Al–Othman, Chihab Ezzaki, Anas Chaari, Anas Chaari
2025-11-18

blood-brain barrierbrain drug deliverychitosan-based nanoparticlesintranasal deliveryreceptor-mediated endocytosis
The blood-brain barrier (BBB) represents a major challenge in effective drug delivery systems intended for treating neurological disorders. It restricts the transport of therapeutic agents to the brain. Chitosan-based nanoparticles (CNPs) can be used for brain drug delivery because of their biocompatibility, biodegradability, and ability to enhance drug permeability across the BBB. This review article discusses the design and application of CNPs for brain-targeted drug delivery, exploring their mechanisms of action, including adsorptive-mediated and receptor-mediated endocytosis. Surface modifications with ligands such as chlorotoxin are discussed for improving specificity and therapeutic results. Findings show that CNPs allow controlled drug release, enhance stability, and reduce side effects, which make them effective for treating multiple neurological conditions, including Alzheimer's disease, Parkinson's disease, brain tumors, and ischemic stroke. CNPs can encapsulate multiple therapeutic agents, such as anti-inflammatory drugs, cytotoxic agents, and genetic materials, and maintain stability under different physiological conditions. Intranasal delivery routes are mainly discussed in this paper for their ability to bypass systemic circulation and achieve direct brain targeting. This review also addresses challenges such as cytotoxicity and the need for optimizing nanoparticle size, charge, and surface properties to improve the therapy results. While CNPs are suitable for brain drug delivery, there is a research gap, which is the lack of systematic studies evaluating their long-term effects on brain tissue and health. Most studies focus on acute therapeutic outcomes and in vitro or short-term in vivo analysis, which do not address some questions about the chronic exposure risks, biodistribution, and clearance pathways of CNPs. This review also explores the use of chitosan-based nanoparticles to deliver drugs to the brain for the treatment of multiple neurological disorders.
1
Chitosan nanoparticles provide controlled drug release, improved drug stability, and reduced side effects across multiple neurological applications.
2
Chitosan-based nanoparticles can enhance therapeutic transport across the blood-brain barrier through adsorptive- and receptor-mediated endocytosis.
3
Important optimization challenges include cytotoxicity and controlling nanoparticle size, charge, and surface properties.
4
Intranasal administration is emphasized as a strategy to bypass systemic circulation and enable direct brain targeting.
5
Long-term effects on brain tissue, chronic exposure risks, biodistribution, and clearance remain insufficiently studied; existing evidence mainly concerns acute or short-term outcomes.
6
Surface functionalization with targeting ligands such as chlorotoxin may improve brain specificity and therapeutic outcomes.
7
These nanoparticles can encapsulate anti-inflammatory drugs, cytotoxic agents, and genetic materials, including for Alzheimer’s disease, Parkinson’s disease, brain tumors, and ischemic stroke.

chitosan-based nanoparticles for brain-targeted drug delivery

their BBB-penetration mechanisms, drug-delivery performance, therapeutic applicability, and safety-related challenges, including controlled release, stability, cytotoxicity, biodistribution, clearance, and long-term effects

Publication Details
Publication Date
2025-11-18
Journal
Publisher
ISSN
Cited by
29
Access Type
Author Information
Authors
Amani Al–Othman
Chihab Ezzaki
Anas Chaari
Anas Chaari
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%